Untangling the Web of Gene Expression
News May 20, 2015
Advancing the development of novel methods for understanding gene expression, Integrated DNA Technologies (IDT) has enabled Dr Jim Hughes, Associate Professor at the Weatherall Institute of Molecular Medicine, Oxford, UK, to optimize his unique Capture-C method, based on Chromosomal Conformational Capture (3C). Dr Hughes uses IDT XGen® Lockdown® Probes to generate highly adaptable target capture probe pools for determining enhancer:promoter interactions, allowing greater flexibility in experimental design.
With enhancers and other regulatory elements often lying 10s to 100s of kilobases from the genes they affect, understanding the regulation of gene expression is an incredibly complex endeavor. Dr Hughes and his collaborators have developed a versatile and scalable solution to enrich for enhancer:promoter interactions by integrating oligo capture and NGS technology into the 3C workflow. Off-the-shelf probe pools or panels often do not match a researcher’s experimental needs, while custom designed probe pools or panels often come at a high cost. Instead, Dr Hughes has utilized IDT’s xGen Lockdown Probes, scaled to create affordable custom probe pools to target specific regions of interest in the genome. He is able to modify the target and perform multiplex assays easily by mixing and augmenting pools with additional probes to create new panels, as required. Using this method, hundreds of genes can be interrogated in the same assay.
Developing this new method has allowed Dr Hughes and his team to enhance their workflow while saving costs as their research interests evolve. Their work has already brought new insight into the currently accepted “looping model” of promoter:enhancer interaction, and has secured Capture-C as a prominent method for addressing gene regulation.
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE
DNA Methylation Related to Liver Disease in Obese PatientsNews
DNA methylation implicated in initiation of liver fibrosis in non-alcoholic fatty liver diseaseREAD MORE
UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPONews
MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018